| 4 | 1/1 | 返回列表 |
| 查看: 624 | 回復(fù): 3 | ||
| 本帖產(chǎn)生 1 個(gè) 翻譯EPI ,點(diǎn)擊這里進(jìn)行查看 | ||
yin198716新蟲 (正式寫手)
|
[求助]
求助翻譯
|
|
| Tumor angiogenesis is essential for tumor growth and metastasis and is triggered by a variety of proangiogenic factors, regulated by many angiogenic pathways. The most important and best characterized is the VEGF pathway . Blockade of VEGF signaling inhibits tumor angiogenesis and growth in various preclinical models and having systemic effects . The effect of anti-VEGF strategy has been validated in randomized phase III clinical trials. Disruption of VEGF signaling by using bevacizumab, a humanized anti-human VEGF antibody or sorafenib and sunitinib, 2 small chemical inhibitors of receptor-tyrosine kinases (RTK) including VEGF receptors have yielded a significant improvement in progression-free survival but rarely in overall survival for patients with several types of cancers including metastatic colorectal cancer , advanced non–small cell lung cancer , metastatic breast cancer , advanced clear-cell renal-cell carcinoma and advanced hepatocellular carcinoma . |


木蟲 (小有名氣)
|
Tumor angiogenesis is essential for tumor growth and metastasis and is triggered by a variety of proangiogenic factors, regulated by many angiogenic pathways. 腫瘤血管新生是腫瘤生長和轉(zhuǎn)移所必需的,它由多種促血管形成因子觸發(fā)并受多種血管新生通路調(diào)控。 The most important and best characterized is the VEGF pathway . 最重要和最有特點(diǎn)的就是VEGF通路。 Blockade of VEGF signaling inhibits tumor angiogenesis and growth in various preclinical models and having systemic effects . 在多種臨床前模型中,阻斷VEGF信號會抑制腫瘤血管新生和腫瘤生長,并且會有系統(tǒng)性的效應(yīng)。 The effect of anti-VEGF strategy has been validated in randomized phase III clinical trials. 抗VEGF策略的作用在隨機(jī)III期臨床試驗(yàn)中得到鞏固。 Disruption of VEGF signaling by using bevacizumab, a humanized anti-human VEGF antibody or sorafenib and sunitinib, 2 small chemical inhibitors of receptor-tyrosine kinases (RTK) including VEGF receptors have yielded a significant improvement in progression-free survival but rarely in overall survival for patients with several types of cancers including metastatic colorectal cancer , advanced non–small cell lung cancer , metastatic breast cancer , advanced clear-cell renal-cell carcinoma and advanced hepatocellular carcinoma . 用貝伐單抗(人源化的抗VEGF抗體)或用索拉非尼和舒尼替尼(受體絡(luò)氨酸激酶的兩種化學(xué)抑制劑) 破壞VEGF信號,可以顯著改善無進(jìn)展生存期,但對同時(shí)患有多種癌癥病人的總體存活率的改善并不大,包括轉(zhuǎn)移性結(jié)直腸癌、晚期非小細(xì)胞肺癌、轉(zhuǎn)移性乳腺癌、晚期透明性腎細(xì)胞癌和晚期肝癌。 收錄到淘貼專輯 |

新蟲 (正式寫手)

| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 生物考研337分求調(diào)劑 +3 | cgxin 2026-03-30 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 哈爾濱工業(yè)大學(xué)材料與化工專碩378求調(diào)劑 +3 | 塔比烏斯 2026-03-30 | 3/150 |
|
|
[考研] 285求調(diào)劑 +6 | AZMK 2026-03-29 | 9/450 |
|
|
[考研] 一志愿中海洋材料357 +3 | 麥恩莉. 2026-03-30 | 3/150 |
|
|
[考研] 環(huán)境工程 085701,267求調(diào)劑 +7 | minht 2026-03-29 | 7/350 |
|
|
[考研] 285求調(diào)劑 +4 | AZMK 2026-03-30 | 7/350 |
|
|
[考研] 327求調(diào)劑 +5 | 小卡不卡. 2026-03-29 | 5/250 |
|
|
[考研] 324求調(diào)劑 +9 | hanamiko 2026-03-26 | 11/550 |
|
|
[考研] 一志愿北京工業(yè)大學(xué),324分求調(diào)劑 +6 | 零八# 2026-03-28 | 6/300 |
|
|
[考研] 311求調(diào)劑 +6 | 冬十三 2026-03-24 | 6/300 |
|
|
[考研] 考研調(diào)劑 +7 | 小蠟新筆 2026-03-29 | 7/350 |
|
|
[考研] 一志愿北京理工大學(xué)本科211材料工程294求調(diào)劑 +8 | mikasa的圍巾 2026-03-28 | 8/400 |
|
|
[考研] 2026年華南師范大學(xué)歡迎化學(xué),化工,生物,生醫(yī)工等專業(yè)優(yōu)秀學(xué)子加入! +3 | llss0711 2026-03-28 | 6/300 |
|
|
[考研] 279求調(diào)劑 +4 | 蝶舞輕繞 2026-03-29 | 4/200 |
|
|
[考研] 298求調(diào)劑 +4 | 種圣賜 2026-03-28 | 4/200 |
|
|
[考研] 308求調(diào)劑 +7 | 墨墨漠 2026-03-25 | 7/350 |
|
|
[考研] 08開頭275求調(diào)劑 +4 | 拉誰不重要 2026-03-26 | 4/200 |
|
|
[考研] 化學(xué)調(diào)劑一志愿上海交通大學(xué)336分-本科上海211 +4 | 小魚愛有機(jī) 2026-03-25 | 4/200 |
|
|
[考研] 求調(diào)劑 +3 | 李李不服輸 2026-03-25 | 3/150 |
|
|
[考研] 一志愿武理085500機(jī)械專業(yè)總分300求調(diào)劑 +3 | an10101 2026-03-24 | 7/350 |
|